DUBLIN--(BUSINESS WIRE)--The "Free Fatty Acid Receptor 4 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Free Fatty Acid Receptor 4 pipeline target constitutes close to 8 molecules. The molecules developed by companies in Phase I and Preclinical stages are 1 and 7 respectively.
This report outlays comprehensive information on the Free Fatty Acid Receptor 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Free Fatty Acid Receptor 4 targeted therapeutics development with respective active and dormant or discontinued projects.
- The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 4
- The report reviews Free Fatty Acid Receptor 4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Free Fatty Acid Receptor 4 targeted therapeutics and enlists all their major and minor projects
- The report assesses Free Fatty Acid Receptor 4 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Free Fatty Acid Receptor 4 targeted therapeutics
Key Topics Covered
- Report Coverage
- Therapeutics Development
- Therapeutics Assessment
- Companies Involved in Therapeutics Development
- Drug Profiles
- Dormant Products
- Product Development Milestones
Featured News & Press Releases
- Nov 12, 2019: Liminal BioSciences presents new preclinical data on NASH candidate PBI-4547
- Oct 25, 2019: Liminal BioSciences announces presentation on its liver disease drug candidate PBI-4547 at The Liver Meeting 2019
- Sep 09, 2019: Prometic reports first subject dosed in phase I clinical study with single ascending doses of PBI-4547
- Jun 22, 2018: Prometic Presents New Data on NASH Drug Candidate PBI-4547
- Oct 20, 2017: Prometic Presents In Vivo Data for PBI-4547 at American Association for the Study of Liver Diseases (AASLD) Meeting
- Jun 12, 2017: Prometic Life Sciences Present Data on PBI-4547 at 2017 American Diabetes Association 77th Scientific Sessions
- AstraZeneca PLC
- CymaBay Therapeutics Inc.
- Dompe Farmaceutici S.p.A.
- GlaxoSmithKline PLC
- Johnson & Johnson
- Liminal BioSciences Inc.
- Merck & Co. Inc.
- Micelle BioPharma Inc.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/59ry0y